Longitudinal study shows increased viral suppression in PLHIV during dolutegravir transition, suggesting improved ART adherence may reduce viremia.
Viral suppression increased during the DTG-transition with minimal emerging intermediate/high-level resistance. Falling resistance among treatment-experienced PLHIV underscores the role of ART adherence in reducing viremia. The emergence of inS153Y justifies continued surveillance.
No takes yet. Share an insight, caveat, or question.
Martín et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: